Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced inducement awards on March 3, 2026 under its 2024 Inducement Plan to six new employees. The grants include 46,000 non‑qualified stock options and 25,875 RSUs.

Options have an exercise price of $39.30 (closing price on March 3, 2026); options and RSUs vest over four years with 25% after one year and remaining vesting monthly or on annual anniversaries (Feb 20 or May 20, 2026) as applicable.

Key Figures

Inducement options: 46,000 shares Inducement RSUs: 25,875 shares Option exercise price: $39.30 per share +5 more

8 metrics

Inducement options 46,000 shares Non-qualified stock options under 2024 Inducement Plan for new employees

Inducement RSUs 25,875 shares Restricted stock units under 2024 Inducement Plan for new employees

Option exercise price $39.30 per share Exercise price equals closing price on March 3, 2026

Option vesting period 4 years 25% after one year, remainder monthly over 36 months

RSU vesting period 4 years 25% of shares vest on each anniversary date

Initial cliff vest 25% First-year vesting portion for options and RSUs

Monthly vesting duration 36 months Remaining option shares vest monthly after first anniversary

New employees 6 employees Recipients of inducement awards under Nasdaq Listing Rule 5635(c)(4)

Market Reality Check

Price: $38.85 Vol: Volume 1,042,140 vs 20-da...

normal vol

$38.85 Last Close

Volume Volume 1,042,140 vs 20-day avg 1,053,577 (relative volume 0.99), indicating typical trading activity. normal

Technical Shares at $38.85, trading above the 200-day MA of $31.61 and about mid-range between the 52-week low $18.53 and high $56.05.

Peers on Argus

VERA slipped -2.02% ahead of the inducement grant news. Among close biotech peer...

1 Down

VERA slipped -2.02% ahead of the inducement grant news. Among close biotech peers, several names like VRDN and ARDX also showed declines (e.g., -4.78%, -5.29%), and momentum data show BHVN down modestly, but only 1 peer appeared in the momentum scanner, suggesting stock-specific rather than broad sector action.

Historical Context

5 past events · Latest: Mar 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 05	Board appointment	Positive	-2.0%	New independent director with substantial biopharma strategic and financial background.
Feb 26	Earnings & update	Positive	+1.6%	Full-year results, positive Phase 3 data, FDA priority review and strong cash position.
Feb 24	Investor conferences	Neutral	+0.7%	Participation in multiple March investor conferences and webcast fireside chat.
Feb 06	Inducement grants	Neutral	+0.8%	Stock options and RSUs granted to new hires under 2024 Inducement Plan.
Jan 28	CCO appointment	Positive	-3.5%	New Chief Commercial Officer to lead atacicept launch readiness for IgAN.

Pattern Detected

Recent news has been dominated by management changes, capital markets updates, and inducement grants. Price reactions have been mixed, with positive fundamental or financing updates often aligning with modest gains, while some leadership appointments have coincided with short-term downside, indicating no consistent one-direction pattern on corporate updates.

Recent Company History

Over recent months, Vera reported several milestones, including a full-year 2025 update on Feb 26, 2026 with positive Phase 3 atacicept data, FDA priority review, a $800 million financing capacity, and $714.6 million cash, which aligned with a +1.61% move. Management changes on Jan 28 and Mar 5 saw negative reactions. Prior inducement grants on Feb 6 were neutral-to-slightly positive with a +0.8% move, providing a close precedent for today’s similar announcement.

Market Pulse Summary

This announcement details inducement grants of 46,000 options and 25,875 RSUs to six new employees a...

Analysis

This announcement details inducement grants of 46,000 options and 25,875 RSUs to six new employees at a $39.30 exercise price, vesting over four years. It follows earlier inducement awards disclosed on Feb 6, 2026, suggesting ongoing hiring ahead of potential atacicept commercialization. Investors may monitor cumulative equity-based compensation, recent net insider selling activity, and upcoming regulatory milestones when assessing overall ownership dilution and alignment with long-term value creation.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, restricted stock units, rsus, +2 more

6 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved the awards as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

class a common stock financial

"to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs)"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

inducement plan financial

"under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan)"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on March 3, 2026 has an exercise price per share equal to $39.30, Vera Therapeutics’ closing trading price on March 3, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of either February 20 or May 20, 2026, depending on the start date of the new employee, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

What inducement awards did Vera Therapeutics (VERA) grant on March 3, 2026?

Vera granted 46,000 non‑qualified stock options and 25,875 RSUs to six new employees. According to the company, the grants were approved under the 2024 Inducement Plan as material inducements under Nasdaq Rule 5635(c)(4).

At what price were the Vera Therapeutics (VERA) stock options granted on March 3, 2026?

Each option was granted with an exercise price of $39.30, equal to Vera's closing price that day. According to the company, that price sets the per‑share exercise amount for the 46,000 options granted.

What is the vesting schedule for the Vera Therapeutics (VERA) inducement stock options?

Options vest over four years with 25% vesting after one year, then monthly over 36 months. According to the company, vesting is contingent on continued service through the applicable vesting dates.

How do the RSU vesting dates work for Vera Therapeutics (VERA) new employees?

Each RSU award vests over four years with 25% on each anniversary of either Feb 20 or May 20, 2026. According to the company, the applicable anniversary depends on the new employee's start date.

Why did Vera Therapeutics (VERA) use inducement grants under Nasdaq Rule 5635(c)(4)?

The inducement grants were approved as material to new employees' employment under Nasdaq Rule 5635(c)(4). According to the company, this permits hiring‑related equity awards outside the existing shareholder plan when meeting Nasdaq requirements.